Notice2023-26736
Government Owned Inventions
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
December 6, 2023
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is directed to a device to measure placental oxygen saturation in pregnant women from 20 weeks of pregnancy to delivery. The device monitors maternal tissue oxygen saturation, blood oxygen saturation, breathing rate, heart rate, and heart rate variability from signal, fetal movement activity and potentially fetal heart rate and heart rate variability. This technology was discovered and is being developed by the National Institute on Child Health and Human Development (NICHD). The NICHD is currently seeking a licensee and/or collaborator to further develop this technology.
Full Text
<html>
<head>
<title>Federal Register, Volume 88 Issue 233 (Wednesday, December 6, 2023)</title>
</head>
<body><pre>
[Federal Register Volume 88, Number 233 (Wednesday, December 6, 2023)]
[Notices]
[Pages 84823-84824]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-26736]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government Owned Inventions
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is directed to a device to measure
placental oxygen saturation in pregnant women from 20 weeks of
pregnancy to delivery. The device monitors maternal tissue oxygen
saturation, blood oxygen saturation, breathing rate, heart rate, and
heart rate variability from signal, fetal movement activity and
potentially fetal heart rate and heart rate variability. This
technology was discovered and is being developed by the National
Institute on Child Health and Human Development (NICHD). The NICHD is
currently seeking a licensee and/or collaborator to further develop
this technology.
FOR FURTHER INFORMATION CONTACT: Inquiries related to this licensing
and collaboration opportunity should be directed to: Zarpheen Jinnah,
Technology Transfer Manager, NCI Technology Transfer Center, 9609
Medical Center Drive, RM 1E530, MSC 9702, Bethesda, MD 20892-9702 (for
business mail), Rockville, MD 20850-9702. Telephone: (240)-276-5530;
[[Page 84824]]
Facsimile: (240)-276-5504; Email: <a href="/cdn-cgi/l/email-protection#62180310120a07070c4c080b0c0c030a220c0b0a4c050d14"><span class="__cf_email__" data-cfemail="146e7566647c71717a3a7e7d7a7a757c547a7d7c3a737b62">[email protected]</span></a>. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to this invention.
SUPPLEMENTARY INFORMATION: The following patent application is
available for licensing and/or collaboration under a Cooperative
Research and Development Agreement (CRADA):
US Provisional Application No. 63/451,066.
Achieving expeditious commercialization of federally funded
research and development is consistent with the goals of the Bayh-Dole
Act, codified as 35 U.S.C. 200-212.
Background and Description of Technology
Monitoring placental oxygenation level and maternal physiological
signals can be useful to assess mother and fetus well-being during
pregnancy. Additionally, fetal movement has long served as a measure
for fetal well-being and nervous system development helping to identify
adverse pregnancy outcomes. Identification of complications during
pregnancy can allow for earlier interventions, including medications to
reduce risk of perinatal mortality and maternal gene therapy.
Researchers at NICHD have created a wearable and wireless device and
protocol for continuously monitoring the placental oxygenation levels,
multiple physiological signals and movement activities of a fetus and
mother. The device includes a compact control board, a flexible near-
infrared spectroscopy (NIRS) probe, and multiple accelerator probes. A
classification algorithm based on Monte-Carlo simulations of multiple
layers model computes oxygen saturation of the placenta. There are one
or more accelerator probes attached to different body parts of the
mother to detect mother movement activities and to eliminate the effect
of mother movement on fetal movement. The overall data acquisition rate
of this device is 10 Hz or more. With this acquisition rate, the output
of the device contains extra physiological signal such as maternal
respiratory and cardiac functions, and fetal cardiac functions.
Potential Commercial Applications
A low cost wearable device, similar to a smart watch, in which a
pregnant woman can wear regularly to monitor both mother and fetus
health conditions.
Competitive Advantages:
<bullet> Wearable and non-invasive placenta and fetal monitoring
device.
<bullet> Capable of 24/7 continuous monitoring of mother and fetal
well-being.
Development Stage
Clinical development.
Dated: November 30, 2023.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2023-26736 Filed 12-5-23; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on December 6, 2023.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.